Triad of hsa-miR-155, hsa-miR-335 and hsa-miR-16 as a Predictor for Recurrence Risk in Gastric Cancer

Abstract

Background and AimsGastric cancer (GC) is one of the most common malignancies and primary causes of death in Chinese cancer patients. Recurrence is a major factor leading to treatment failure and low 5-year survival rates following surgical resection. A major challenge in improving clinical outcomes is identifying robust signatures for the prognosis of GC. This study aimed to find plasma microRNAs (miRNAs) with considerable clinical value in predicting GC recurrence.MethodsA total of 46 GC patients were selected for systematic analysis: 16 patients with recurrence and 30 patients without recurrence. Microarray assay was used to screen for miRNAs in plasma samples (n=8) from stage II patients with recurrence and stage III patients without recurrence. Subsequently, quantitative reverse-transcriptase polymerase chain reaction assay was applied to evaluate the expression of selected miRNAs both in plasma samples and in fresh frozen tissue samples (n=38).ResultsThe study identified 19 miRNAs with differential expression, including 11 upregulated and 8 downregulated miRNAs, in the recurrence group. Using partial least squares regression, we further ascertained the triad of hsa-miR-155, hsa-miR-335 and hsa-miR-16 as a classifier to recognize recurrence and non-recurrence cases both in the training and the test samples. Moreover, we validated this classifier in 24 fresh frozen tissue samples and plasma samples with consistent sensitivity and specificity. A high frequency of recurrence and poor survival were observed in GC cases with high levels of hsa-miR-155 and hsa-miR-335, and low levels of hsa-miR-16 (P < .001).ConclusionsOur results suggest that the triad of hsa-miR-155, hsa-miR-335 and hsa-miR-16 has the potential to predict the risk of recurrence in GC patients. Background and AimsGastric cancer (GC) is one of the most common malignancies and primary causes of death in Chinese cancer patients. Recurrence is a major factor leading to treatment failure and low 5-year survival rates following surgical resection. A major challenge in improving clinical outcomes is identifying robust signatures for the prognosis of GC. This study aimed to find plasma microRNAs (miRNAs) with considerable clinical value in predicting GC recurrence. Gastric cancer (GC) is one of the most common malignancies and primary causes of death in Chinese cancer patients. Recurrence is a major factor leading to treatment failure and low 5-year survival rates following surgical resection. A major challenge in improving clinical outcomes is identifying robust signatures for the prognosis of GC. This study aimed to find plasma microRNAs (miRNAs) with considerable clinical value in predicting GC recurrence. MethodsA total of 46 GC patients were selected for systematic analysis: 16 patients with recurrence and 30 patients without recurrence. Microarray assay was used to screen for miRNAs in plasma samples (n=8) from stage II patients with recurrence and stage III patients without recurrence. Subsequently, quantitative reverse-transcriptase polymerase chain reaction assay was applied to evaluate the expression of selected miRNAs both in plasma samples and in fresh frozen tissue samples (n=38). A total of 46 GC patients were selected for systematic analysis: 16 patients with recurrence and 30 patients without recurrence. Microarray assay was used to screen for miRNAs in plasma samples (n=8) from stage II patients with recurrence and stage III patients without recurrence. Subsequently, quantitative reverse-transcriptase polymerase chain reaction assay was applied to evaluate the expression of selected miRNAs both in plasma samples and in fresh frozen tissue samples (n=38). ResultsThe study identified 19 miRNAs with differential expression, including 11 upregulated and 8 downregulated miRNAs, in the recurrence group. Using partial least squares regression, we further ascertained the triad of hsa-miR-155, hsa-miR-335 and hsa-miR-16 as a classifier to recognize recurrence and non-recurrence cases both in the training and the test samples. Moreover, we validated this classifier in 24 fresh frozen tissue samples and plasma samples with consistent sensitivity and specificity. A high frequency of recurrence and poor survival were observed in GC cases with high levels of hsa-miR-155 and hsa-miR-335, and low levels of hsa-miR-16 (P < .001). The study identified 19 miRNAs with differential expression, including 11 upregulated and 8 downregulated miRNAs, in the recurrence group. Using partial least squares regression, we further ascertained the triad of hsa-miR-155, hsa-miR-335 and hsa-miR-16 as a classifier to recognize recurrence and non-recurrence cases both in the training and the test samples. Moreover, we validated this classifier in 24 fresh frozen tissue samples and plasma samples with consistent sensitivity and specificity. A high frequency of recurrence and poor survival were observed in GC cases with high levels of hsa-miR-155 and hsa-miR-335, and low levels of hsa-miR-16 (P < .001). ConclusionsOur results suggest that the triad of hsa-miR-155, hsa-miR-335 and hsa-miR-16 has the potential to predict the risk of recurrence in GC patients. Our results suggest that the triad of hsa-miR-155, hsa-miR-335 and hsa-miR-16 has the potential to predict the risk of recurrence in GC patients.